Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BRAF L485-P490 deletion (6)
BRAF amplification (1)
BRAF L485-P490 deletion (6)
BRAF amplification (1)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600
Non Small Cell Lung Cancer
BRAF V600
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600
Glioma
BRAF V600
Glioma
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
tovorafenib
Sensitive: A1 - Approval
tovorafenib
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
trametinib
Resistant: A2 - Guideline
trametinib
Resistant
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.